Are TRT clinics actually underdosing testosterone patients?

What did @socalurologyinstitute actually say?

A urologist with claimed 25 years of experience argued that most TRT clinics waste patients' time by titrating doses slowly upward. His position: "most men between 175 pounds and 225 pounds need 200 milligrams of testosterone a week," and that starting patients there from day one, then checking labs at three months, is simply the smarter approach. He dismisses gradual dose escalation as a money-generating scheme of repeat visits and blood draws. His recommendation applies not just to average-sized men, but to smaller individuals too, suggesting 150mg weekly for someone around 120 pounds. The throughline is confidence: "Your perfect dose is 200 milligrams."

To be clear about what he is actually doing here: this is a clinician publicly recommending a specific testosterone dose to an anonymous mass audience based on body weight alone, with no individual clinical evaluation. That framing matters for everything that follows.

Does the science back this up?

Partly, and with serious caveats. The evidence that low-dose initiation strategies prolong time-to-symptom-resolution is real, but the idea that 200mg weekly is universally appropriate is not supported by clinical guidelines or pharmacokinetic data.

The Endocrine Society's 2018 clinical practice guidelines (Bhasin et al., Journal of Clinical Endocrinology and Metabolism) recommend titrating testosterone cypionate or enanthate to achieve mid-normal physiologic levels, targeting roughly 400-700 ng/dL, not a fixed milligram dose. The reason is straightforward: absorption, metabolism, and baseline endogenous production vary significantly between individuals. A 2020 pharmacokinetic analysis by Pastuszak et al. in the Journal of Urology confirmed that serum testosterone response to equivalent doses varies by as much as 40-50% between patients. Dosing by body weight alone does not account for SHBG levels, hepatic clearance, or injection frequency sensitivity. The creator's frustration with excessive titration visits has merit. Overly conservative prescribing that drags out treatment unnecessarily is a documented problem in men's health. But the solution he offers, a one-size-fits-many starting dose without baseline labs informing that number, trades one clinical shortcut for another.

What did they get wrong (or right)?

He gets credit for one real thing: the slow titration problem is legitimate. Some clinics do run patients through repeated low-dose adjustments that serve billing more than outcomes. Studies on hypogonadal men show that prolonged symptomatic periods before adequate testosterone levels are achieved worsen quality-of-life metrics (Zitzmann et al., 2006, European Urology). That frustration is clinically grounded.

What he gets wrong is more significant. "God forbid it's a little high. Nothing bad is gonna happen" is a claim that contradicts the pharmacology. Supraphysiologic testosterone levels, which 200mg weekly can produce in many men, are associated with erythrocytosis (hematocrit elevation), which increases thrombosis risk. The Testosterone Trials (Snyder et al., 2016, New England Journal of Medicine) flagged cardiovascular signal concerns even at doses targeting physiologic ranges. Elevated estradiol from aromatization at higher doses causes gynecomastia and can suppress gonadotropin feedback acutely. Starting at 200mg without baseline labs also means prescribing blind. You do not know a patient's hematocrit, PSA, or natural testosterone production before beginning. That is not efficient medicine. That is skipping steps that exist for safety reasons.

• Getting right: gradual micro-titration for its own sake can delay effective treatment
• Getting wrong: 200mg weekly is not a universal safe starting dose
• Getting wrong: dismissing inter-individual variability in testosterone metabolism
• Getting wrong: "nothing bad is gonna happen" at high-normal or supraphysiologic levels

What should you actually know?

TRT dosing is individualized medicine, and no credible guideline recommends a population-level fixed dose based on body weight. What the evidence supports is achieving a target serum level, not a target milligram number. For testosterone cypionate administered weekly, doses between 100mg and 200mg weekly are common, but where a specific patient lands depends on their baseline testosterone, SHBG, injection frequency, and symptom response. The three-month lab recheck he recommends is actually reasonable timing for steady-state assessment. That part is not controversial.

If you are considering TRT or are currently on it, the questions worth asking your provider are not "why am I not on 200mg" but rather: what is my total and free testosterone at trough, what is my hematocrit, and does my current dose reflect my actual lab values. Erythrocytosis is the most common TRT side effect and it is dose-dependent (Bachman et al., 2010, Journal of Clinical Endocrinology and Metabolism). That alone is a reason to not treat dose escalation as low-stakes. Starting higher and adjusting down is not inherently safer than starting lower and adjusting up. Both require monitoring. The difference is what you are monitoring for.